
Global Therapies and Diagnostics for Ovarian Cancer Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Therapies and Diagnostics for Ovarian Cancer market size will reach US$ 2874 million by 2031.
Ovarian cancer (ovarian cancer) accounts for 2.4% ~ 6.5% of the common malignant tumors in women, and ranks the third among the cancers of the female reproductive system, secondary to cervical cancer and uterine body cancer.In recent years, due to the prevention and treatment of cervical cancer and uterine body cancer, some achievements have been made, while the prevention and treatment of ovarian cancer is relatively small.So ovarian cancer is the leading cause of death among cancers of the reproductive system in women.
United States market for Therapies and Diagnostics for Ovarian Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Therapies and Diagnostics for Ovarian Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Therapies and Diagnostics for Ovarian Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Therapies and Diagnostics for Ovarian Cancer players cover Astra Zeneca, Clovis Oncology, Myriad, TESARO, AbbVie Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Therapies and Diagnostics for Ovarian Cancer Industry Forecast” looks at past sales and reviews total world Therapies and Diagnostics for Ovarian Cancer sales in 2024, providing a comprehensive analysis by region and market sector of projected Therapies and Diagnostics for Ovarian Cancer sales for 2025 through 2031. With Therapies and Diagnostics for Ovarian Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Therapies and Diagnostics for Ovarian Cancer industry.
This Insight Report provides a comprehensive analysis of the global Therapies and Diagnostics for Ovarian Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Therapies and Diagnostics for Ovarian Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Therapies and Diagnostics for Ovarian Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Therapies and Diagnostics for Ovarian Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Therapies and Diagnostics for Ovarian Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Therapies and Diagnostics for Ovarian Cancer market by product type, application, key players and key regions and countries.
Segmentation by Type:
Surgery
Radiation Therapy
Drug Treatment
Segmentation by Application:
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Astra Zeneca
Clovis Oncology
Myriad
TESARO
AbbVie Inc
Celgene
Janssen Pharmaceuticals
Merck
Novartis AG
Quest Diagnostics Inc
Please note: The report will take approximately 2 business days to prepare and deliver.
Ovarian cancer (ovarian cancer) accounts for 2.4% ~ 6.5% of the common malignant tumors in women, and ranks the third among the cancers of the female reproductive system, secondary to cervical cancer and uterine body cancer.In recent years, due to the prevention and treatment of cervical cancer and uterine body cancer, some achievements have been made, while the prevention and treatment of ovarian cancer is relatively small.So ovarian cancer is the leading cause of death among cancers of the reproductive system in women.
United States market for Therapies and Diagnostics for Ovarian Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Therapies and Diagnostics for Ovarian Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Therapies and Diagnostics for Ovarian Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Therapies and Diagnostics for Ovarian Cancer players cover Astra Zeneca, Clovis Oncology, Myriad, TESARO, AbbVie Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Therapies and Diagnostics for Ovarian Cancer Industry Forecast” looks at past sales and reviews total world Therapies and Diagnostics for Ovarian Cancer sales in 2024, providing a comprehensive analysis by region and market sector of projected Therapies and Diagnostics for Ovarian Cancer sales for 2025 through 2031. With Therapies and Diagnostics for Ovarian Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Therapies and Diagnostics for Ovarian Cancer industry.
This Insight Report provides a comprehensive analysis of the global Therapies and Diagnostics for Ovarian Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Therapies and Diagnostics for Ovarian Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Therapies and Diagnostics for Ovarian Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Therapies and Diagnostics for Ovarian Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Therapies and Diagnostics for Ovarian Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Therapies and Diagnostics for Ovarian Cancer market by product type, application, key players and key regions and countries.
Segmentation by Type:
Surgery
Radiation Therapy
Drug Treatment
Segmentation by Application:
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Astra Zeneca
Clovis Oncology
Myriad
TESARO
AbbVie Inc
Celgene
Janssen Pharmaceuticals
Merck
Novartis AG
Quest Diagnostics Inc
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
100 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Therapies and Diagnostics for Ovarian Cancer Market Size by Player
- 4 Therapies and Diagnostics for Ovarian Cancer by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Therapies and Diagnostics for Ovarian Cancer Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.